Skip to main content

Advertisement

SpringerLink
Log in

Impact of adjuvant therapy toxicity on quality of life and emotional symptoms in patients with colon cancer: a latent class analysis

  • Brief Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Objective

To identify distinct trajectories of toxicity in colorectal cancer (CRC) patients after adjuvant chemotherapy and its impact on quality of life (QoL) and psychological symptoms.

Methods

A prospective, multicenter study was conducted in 157 patients. A latent class analysis defined the unobserved latent constructs that can be predicted as symptom clusters, considering the intensity of four types of adverse events (AEs). Patients completed EORTC-QLQ-C30, BSI-18, PDRQ-9, and DRS scales.

Results

Ninety-six percent had some degree of toxicity, with grades 3–4 being the most common: neurotoxicity (7.2%), hematological (13.1%), digestive (5.2%), and skin toxicity (1.4%). Three distinct latent classes were identified (high [72.5%], mild [16.9%], and low [10.6%] toxicity). Patients with high toxicity had the worst QoL scores and moderately high somatization and psychological distress scores.

Conclusions

Adjuvant chemotherapy for CRC was associated with frequent toxicity that negatively impacted QoL and psychological wellbeing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

    Article  Google Scholar 

  2. Edge SB, Byrd DR, Carducci MA, Compton CC, Fritz AG, Greene FL. AJCC cancer staging manual. New York: Springer; 2010.

    Google Scholar 

  3. Weiser MR, Landmann RG, Kattan MW, Gonen M, Shia J, Chou J, et al. Individualized prediction of colon cancer recurrence using a nomogram. J Clin Oncol. 2008;26:380–5.

    Article  Google Scholar 

  4. Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004;22:1797–806.

    Article  CAS  Google Scholar 

  5. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109–16.

    Article  Google Scholar 

  6. Haller DG, Tabernero J, Maroun J, De Braud F, Price T, Van Cutsem E, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29:1465–71.

    Article  CAS  Google Scholar 

  7. Yothers G, O’Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29:3768.

    Article  CAS  Google Scholar 

  8. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.

    Article  CAS  Google Scholar 

  9. Derogatis LR. BSI 18, Brief symptom inventory 18: administration, scoring and procedures manual. Incorporated: NCS Pearson; 2001.

    Google Scholar 

  10. Van der Feltz-Cornelis CM, Van Oppen P, Van Marwijk HWJ, De Beurs E, Van Dyck R. A patient-doctor relationship questionnaire (PDRQ-9) in primary care: development and psychometric evaluation. Gen Hosp Psychiatry. 2004;26:115–20.

    Article  Google Scholar 

  11. Brehaut JC, O’Connor AM, Wood TJ, Hack TF, Siminoff L, Gordon E, et al. Validation of a decision regret scale. Med Decis Mak. 2003;23:281–92.

    Article  Google Scholar 

  12. Calderon C, Ferrando PJ, Lorenzo-Seva U, Higuera O, y Cajal TR, Rogado J, et al. Validity and reliability of the decision regret scale in cancer patients receiving adjuvant chemotherapy. J Pain Symptom Manage. 2019;57:828–34.

    Article  Google Scholar 

  13. Collins LM, Lanza ST. Latent class and latent transition analysis: With applications in the social, behavioral, and health sciences. 1st ed. Hoboken: John Wiley & Sons; 2010.

    Google Scholar 

  14. Hagenaars JA, McCutcheon AL. Applied latent class analysis. Cambridge: Cambridge University Press; 2002.

    Book  Google Scholar 

  15. Shah MA, Renfro LA, Allegra CJ, André T, De Gramont A, Schmoll H-J, et al. Impact of patient factors on recurrence risk and time dependency of oxaliplatin benefit in patients with colon cancer: analysis from modern-era adjuvant studies in the adjuvant colon cancer end points (ACCENT) database. J Clin Oncol. 2016;34:843.

    Article  CAS  Google Scholar 

  16. García-García T, Carmona-Bayonas A, Jimenez-Fonseca P, Jara C, Beato C, Castelo B, et al. Biopsychosocial and clinical characteristics in patients with resected breast and colon cancer at the beginning and end of adjuvant treatment. BMC Cancer. 2019;19:1143.

    Article  Google Scholar 

Download references

Acknowledgements

We thank Priscilla Chase Duran for editing the manuscript; Natalia Cateriano, Miguel Vaquero, and IRICOM S.A. for supporting the registry website

Funding

This study was supported by the FSEOM-Onvida for Projects on Long Survivors and Quality of Life. SEOM (Spanish Society of Medical Oncology) 2015.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Hospital Universitario Central de Asturias, ISPA, University of Pais Vasco, Pais Vasco, Avenida Roma sn, 33011, Oviedo, Spain

    D. Gomez & P. Jimenez-Fonseca

  2. Department of Clinical Psychology and Psychobiology, Faculty of Psychology, University of Barcelona, University of Pais Vasco, Pais Vasco, Barcelona, Spain

    C. Calderón

  3. Department of Medical Oncology, Hospital Universitario Morales Meseguer, UMU, IMI, Murcia, Spain

    A. Carmona-Bayonas

  4. Department of Medical Oncology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain

    D. Cacho Lavin

  5. Department of Medical Oncology, Hospital Universitario Virgen de La Luz, Cuenca, Spain

    M. M. Muñoz

  6. Department of Medical Oncology, Hospital Universitario Fundación Alcorcón, Madrid, Spain

    R. Martinez Cabañez

Authors
  1. D. Gomez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Calderón
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Carmona-Bayonas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D. Cacho Lavin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. M. Muñoz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R. Martinez Cabañez
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P. Jimenez-Fonseca
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Jimenez-Fonseca.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest. This is an academic study.

Ethical approval

This study was performed in accordance with the ethical standards of the Declaration of Helsinki and its later amendments. It is an observational, non-interventional trial.

Informed consent

Signed informed consent was obtained from all patients.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Annexed Table: Participating centers

Annexed Table: Participating centers

  1. 1.

    Hospital Universitario de Canarias, Tenerife

  2. 2.

    Hospital Universitario Central de Asturias, Oviedo

  3. 3.

    Hospital Universitario La Paz, Madrid

  4. 4.

    Hospital Universitario Morales Meseguer, Murcia

  5. 5.

    Hospital Universitario Fundación Alcorcon, Madrid

  6. 6.

    Hospital Universitario Marqués de Valdecilla, Santander

  7. 7.

    Hospital Universitario Virgen de La Luz, Cuenca

  8. 8.

    Grupo Hospitalario Quirón, Sevilla

  9. 9.

    Hospital Universitario Son Espases, Mallorca

  10. 10.

    Hospital Universitario Santa Creu i Sant Pau, Barcelona

  11. 11.

    Hospital Universitario Insular de Gran Canaria, Las Palmas

  12. 12.

    Hospital Universitario La Princesa, Madrid

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gomez, D., Calderón, C., Carmona-Bayonas, A. et al. Impact of adjuvant therapy toxicity on quality of life and emotional symptoms in patients with colon cancer: a latent class analysis. Clin Transl Oncol 23, 657–662 (2021). https://doi.org/10.1007/s12094-020-02454-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-020-02454-z

Keywords

Search

Navigation